Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids

M. Benucci, Gianantonio Saviola, P. Baiardi, L. Abdi-Ali, M. R. Povino, S. Dolenti, L. Campostrini, S. Sacco, M. Manfredi, M. Rossini

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To assess the effects of intramuscular (im) neridronate (NE) on lumbar and femoral neck BMD and on markers of bone turnover in rheumatic patients under chronic low-dose glucocorticoids (GC) therapy. Methods: Sixty-nine osteopoenic and osteoporotic patients, affected by rheumatic diseases and gastric or esophageal conditions which contraindicated treatment with oral bisphosphonates (BPs), were randomly assigned to: Group A (23 patients) administered with daily calcium 1 g and vitamin D 800 UI; Group B (46 patients) receiving daily calcium 1 g, vitamin D 800 UI and im NE 25 mg monthly. Results: After 12 months of therapy (M12) lumbar BMD was reduced of 2.97% in Group A, and improved of 3.34% (p=0.001) in Group B; at M12, femoral neck BMD was reduced of 2.40% in Group A and improved of 1.78% in Group B (p=0.010). After 6 (M6) and 12 months of therapy, the bone resorption markers were significantly reduced in Group B: OHPr-41.64% at M6 (p

Original languageEnglish
Pages (from-to)567-573
Number of pages7
JournalClinical and Experimental Rheumatology
Volume27
Issue number4
Publication statusPublished - Jul 2009

Keywords

  • Bisphophonates
  • Bone markers
  • Glucocorticoid induced osteoporosis
  • Neridronate
  • Rheumatic diseases

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids'. Together they form a unique fingerprint.

Cite this